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Abstract. Background/Aim: Invariant natural killer T-cells
(iNKT) stimulated by CD1d-binding glycolipids have been
shown to exert antitumor effects by a number of studies in a
mouse model. Breast cancer is a devastating disease, with
different types of breast cancer recurring locally or distant as
metastatic/advanced disease following initial treatment. The aim
of this study was to examine the tumoricidal effect of a CD1d-
binding glycolipid, called 7DW8-5, against a highly invasive
human breast cancer cell line both in vitro and in vivo. Materials
and Methods: Parental MDA-MB-231 cells and MDA-MB-231
cells transduced with human CD1d were labeled with
carboxyfluorescein diacetate succinimidyl ester (CFSE),
followed by loading with glycolipids. After co-culturing with
human iNKT cells, the cells were permeabilized and stained with
Alexa Flour 647-conjugated antibody to active caspase-3, and
analyzed using a BD LSR II. For the in vivo tumoricidal effect,
MDA-MB-231 cells transduced with human CD1d and
luciferase genes were injected into the mammary fat pad of
female NOD/SCID/IL2rγnull (NSG) mice, followed by the
injection of human iNKT cells with or without 7DW8-5, and the
levels of luminescence were analyzed with whole-body imaging.
Results: Human iNKT cells could kill CD1d-expressing human
breast cancer cells in vitro in the presence of 7DW8-5, but not
α-GalCer. As for in vivo, the adoptive transfer of human iNKT
cells into tumor-challenged NSG mice significantly inhibited the
growth of CD1d+ MDA-MB-231 human breast cancer cells in
the presence of 7DW8-5. Conclusion: CD1d-binding, glycolipid-
based iNKT-cell therapy is suggested as a potent and effective
treatment against breast cancer in humans.
Breast cancer is a devastating disease, with different types
of breast cancer recurring locally (1, 2) or distant as
metastatic/advanced disease (3) following initial treatment.
Metastatic breast cancer usually occurs from months to years
after first treatment, and is typically found in the lungs, liver,
bones or brain. Nonetheless, breast cancer recurrence is
different in each patient; those differences are based on
tumor biology (e.g. hormone receptor status), stage of
disease when first diagnosed, or even on the chemotherapy
received by the patient following diagnosis. A recent and
promising treatment approach against various forms of
cancer is immunotherapy, which takes advantage of the
patient’s own immune system to attack the tumor cells. 
Natural killer T-cells (NKT) are a unique subset of T-cells
that share properties of both T-cells and natural killer cells. NKT
cells recognize lipid antigens presented by the non-polymorphic
major histocompatibility complex (MHC) class I-like molecule,
CD1d (4-6). There are two major subpopulations of NKT cells:
Type I NKT cells, also called invariant NKT (iNKT) cells, and
type II NKT cells (7-10). The prototypic antigen for type I NKT
cells is α-galactosylceramide (α-GalCer), which stimulates
iNKT cells to release large amounts of interferon-γ (IFNγ),
which helps activate both CD8+ T-cells and antigen-presenting
cells such as dendritic cells (DCs) and macrophages (11, 12).
Functionally, type I NKT cells exert a protective immune
response against tumors (13-17), whereas type II NKT cells are
typically associated with immunosuppression (18, 19). More
recently, we identified a synthetic analog of α-GalCer, named
7DW8-5, which elicits the most potent iNKT-cell response
among 100 analogs tested (20). As shown in Figure 1A, this
analog differs from α-GalCer in that it possesses a fluorinated
benzene ring at the end of a C8 length fatty acyl chain (20).
Thus, 7DW8-5 has been shown to have stronger bioactivity
towards iNKT cells and CD1d-bearing DCs (20-26). In
addition, 7DW8-5 also has tumoricidal activity against human
medulloblastoma in vivo, using humanized mice (17). 
In the current study, using a highly invasive and poorly
differentiated triple-negative breast cancer cell line, MDA-
MB-231, we investigated the ability of α-GalCer and its
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analog, 7DW8-5, to display NKT cell-dependent cytotoxicity
against these human breast cancer cells in vitro; we then
analyzed the in vivo antitumor-activating activity of 7DW8-5
using immunodeficient mice.
Materials and Methods
Animals, glycolipids and a human breast cancer cell line, MDA-
MB-231. A total of 13 female NOD/SCID/IL2rγnull (NSG) mice
were purchased from The Jackson Laboratory (Bar Harbor, ME,
USA) and maintained under specific pathogen-free conditions in
the animal facilities at the Comparative Bioscience Center of The
Rockefeller University. α-GalCer was purchased from Enzo Life
Sciences (Farmingdale, NY, USA). 7DW8-5 was synthesized as
previously described (20). The structural difference between the
two glycolipids is shown in Figure 1A. A human breast cancer cell
line, MDA-MB-231, which is a highly aggressive, invasive and
poorly differentiated triple-negative breast cancer cell line that
lacks estrogen receptor (ER) and progesterone receptor (PR)
expression, as well as human epidermal growth factor receptor 2
(27, 28), was purchased from the American Type Culture
Collection (Manassas, VA, USA).
A human breast cancer cell line transduced with human CD1d and
luciferase genes. A human CD1d-human β2-microglobulin (β2m)
(hCD1d–hβ2m) gene was amplified with polymerase chain reaction
from a plasmid consisting of a human CD1d gene covalently linked
to a human β2m gene that was previously constructed in our
laboratory (26). A firefly luciferase (Luc) gene was amplified from a
plasmid that was previously established in our laboratory (29). The
amplified hCD1d–hβ2m gene and Luc gene were then linked with a
T2A linker sequence (ggaagcggagagggcagaggaagtctgctaacatgcggtg
acgtcgaggagaatcctggacct). The hCD1d–hβ2m-T2A linker-Luc gene
complex was then inserted into a lentivirus vector, pLV-EF1a-IRES-
Blast, purchased from Addgene (Cambridge, MA, USA) (30), using a
Gibson Assembly® method (New England Biolabs, Ipswich, MA,
USA) (31, 32). The final constructs were verified with Sanger
sequencing. Viral supernatants were produced by the transfection of
5×106/10 mI 293 T-cells in 10-cm petri dishes with 8 μg of the CD1d-
Luc plasmid, and the packaging plasmids, psPAX2 (6.5 μg; Addgene)
and pMD2.G (2 μg; Addgene) for 24 h. MDA-MB-231 cells (4×105)
in 12-well plates were infected with 2 mI of the viral supernatants
followed by antibiotic selection with 8 μg/ml of blasticidin.
(ThermoFisher Scientific, Waltham, MA, USA). After 16-17 days, the
successful infection and transduction of human CD1d were confirmed
by staining the infected cancer cell line with an allophycocyanin-
labeled anti-human CD1d antibody (BioLegend, San Diego, CA,
USA), followed by a flow cytometric assay. The successful
transduction and expression of Luc were confirmed by measuring the
in vitro firefly luciferase activity, using luminometry (33).
In vitro cytotoxic effects of human iNKT cells against human breast
cancer cells. Parental MDA-MB-231 cells and MDA-MB-231 cells
transduced with human CD1d were labeled with carboxyfluorescein
diacetate succinimidyl ester (CFSE; Molecular Probes, Eugene, OR,
USA) (34, 35), followed by loading with the respective glycolipid
at 0.1 μg/mI for 30 min. Human iNKT cell lines were established
from peripheral blood mononuclear cells, as described elsewhere
(36). CFSE-labeled MDA-MB-231 cells pulsed with glycolipid
(1×105) in 100 μl were then mixed with the same number and
volume of human iNKT cells as effector cells, in conical
polypropylene Costar cluster tubes (Costar, Corning, NY, USA).
The cell mixture was centrifuged at low speed (10 × g) for 1 min
and incubated for 5 h at 37˚C (34, 37). The cells were then washed
with culture media at room temperature, and permeabilized with
Cytofix/Cytoperm solution (BD Biosciences, San Jose, CA, USA)
for intracellular staining. Next, the cells were washed twice with
Perm/Wash buffer (BD Biosciences) and resuspended in staining
buffer. After incubation for 1 h on ice with Alexa Fluor 647-
conjugated monoclonal antibody to active caspase-3 (BD
Biosciences) (38, 39), the cells were washed and analyzed using a
BD LSR II instrument (BD Biosciences).
A less invasive orthotopic injection of human breast cancer cells
into the mammary fat pad of female NSG mice. Human breast
cancer cells were inoculated into the mammary fat pad of female
NSG mice as described elsewhere (40). Briefly, the mice were
first anesthetized using 3% inhalant isoflurane. Hair around the
abdominal and inguinal fat pads was trimmed and the skin was
sterilized with alcohol. With the aid of magnifying surgical
loupes, a small incision of less than 3 mm was made externally
and caudally to the fourth nipple. The nipple was then lifted, and
with the tip of a micro-dissecting scissor blade, the skin was
detached from the fascia below and the fat pad exposed. Two
million MDA-MB-231/Luc/hCD1d cells were then injected into
the fat pad in a small volume (<100 μl) using an insulin syringe.
With the aid of a Q-Tip dipped in an antibiotic mixture solution,
the exposed fat pad was gently pushed inward, allowing it to
easily glide back into place. Finally, the small incision was sealed
using tissue adhesive (Vetbond; 3M, St Paul, MN, USA),
followed by applying post-operative analgesia (bupivacaine) to
the area. 
Luciferase expression by noninvasive bioluminescent imaging. On
3, 10, 20 and 30 days after intra-mammary fat pad injection of
MDA-MB-231/Luc/hCD1d cells, whole-body images of luciferase
expression in NSG mice were monitored using IVIS®Lumina with
Living Image software (Caliper LifeScience, Hopkinton, MA,
USA), as we and others have described (29, 34). Briefly, after
anesthetizing the mice, 200 μl of 15 mg/ml D-luciferin (Gold
Biotechnology, St Louis, MO, USA) was injected intra-peritoneally,
and whole-body in vivo imaging analysis was performed for 30 s to
2 min, using an in vivo imaging system (IVIS®Lumina). Luciferase
expression data were then quantified using Living Image software
(Caliper LifeScience) in a fixed region of interest in terms of
photons/s/cm2/sr.
Data analysis. Statistical analysis of experimental and control data
was evaluated by Student’s t-test. A value of p<0.05 was considered
statistically significant. Statistical analysis of survival rates was
performed by using Gehan-Breslow Wilcoxon test, as previously
described (25).
Results
In vitro cytotoxic effects of human iNKT cells triggered by
α-GalCer versus 7DW8-5 against human breast cancer
cells. We first established a human breast cancer line that
expresses human CD1d, namely MDA-MB231/hCD1d, by
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Figure 1. Structure of glycolipids 7DW8-5 and α-galactosylceramide (α-GalCer) and their ability to trigger cytotoxic activity of human invariant
natural killer T- (iNKT) cells against human breast cancer cells in vitro. A: Structural comparison of 7DW8-5 and α-GalCer. B: The expression of
human CD1d by MDA-MB-231/hCD1d cells, but not by MDA-MB231 cells by flow cytometric analysis. C: Human iNKT cells were used as effector
cells. MDA-MB-231 and MDA-MB-231/hCD1d cells were labeled with carboxyfluorescein diacetate succinimidyl ester (CFSE), and used as target
cells. These two cell populations were co-cultured in the presence or absence of the respective glycolipid, and in-vitro CTL assays were performed
by measuring the amount of caspase-3 within the target cells. D: Quantification of the data shown in C. Data are shown from one of three
independent experiments with similar results.
transducing MDA-MB231 line with a plasmid consisting of
a human CD1d gene covalently linked to a human β2m
gene, as described in the Materials and Methods. Figure 1B
shows successful expression of human CD1d by MDA-
MB231/hCD1d cells as shown by flow cytometric analysis.
In order to determine the in vitro cytotoxic activity of α-
GalCer and its analog 7DW8-5, the human breast cancer
lines MDA-MB231 and MDA-MB231/hCD1d were labeled
with CFSE, and used as target cells. After establishing
human iNKT cell lines, we co-cultured the human breast
cancer line with the human iNKT cell line as effector cells
in the presence or absence of α-GalCer or 7DW8-5. As
shown in Figure 1C and D, we found that human iNKT
cells exerted significant in vitro cytotoxic activity against
7DW8-5-pulsed, but not against α-GalCer-pulsed or non-
pulsed MDA-MB-231 cells that co-expressed human CD1d,
as determined by the level of active caspase-3 activity.
Neither of the glycolipids was able to induce killing
activity against CD1d-deficient MDA-MB-231 cells (Figure
1C and D).
In vivo tumoricidal effect of 7DW8-5 against human breast
cancer cells. Next, we assessed the antitumor effects of
7DW8-5 against the human MDA-MB-231 breast cancer line
in vivo using immunodeficient NSG mice. These highly
immunodeficient mice lack almost the entire mouse-derived
immune system, including murine B-cells, T-cells, and NK
cells (41). We first inoculated 2×106 MDA-MB-
231/Luc/hCD1d cells into female NSG mice using a less
invasive orthotopic injection into the mammary fat pad (40).
Four and 11 days later, 200 μl of medium containing 4×106
human iNKT cells and 0.1 μg of 7DW8-5, or human iNKT
cells only or PBS as a control, was administered
intravenously to a group of tumor-challenged mice. Finally,
we assessed the levels of luminescence by whole-body in
vivo imaging on days 3, 10, 20 and 30 post-tumor
inoculation (Figure 2A). We first ensured that the tumor
masses were established in all NSG mice challenged with
MDA-MB-231/Luc/hCD1d cells before treating with human
iNKT cells/7DW8-5, as determined by IVIS (Figure 2C). We
then observed that both groups of NSG mice that received
human iNKT cells and 7DW8-5, as well as human iNKT
cells only, showed a lower luciferase signal on day 27 post
treatment (Figure 2B and C). Nevertheless, a statistical
difference was only observed between a group of NSG mice
that received human iNKT cells and 7DW8-5, as compared
with PBS-treated mice (Figure 2C). Furthermore, compared
to the PBS-treated mice, all four NSG mice that received
human iNKT cells and 7DW8-5 survived significantly longer
upon tumor challenge (Figure 2D). When we challenged
mice with MDA-MB-231/Luc cells that lacked human CD1d
gene expression, the glycolipids failed to exert a significant
antitumor effect (data not shown). 
Discussion
NKT cells, an innate cytotoxic lymphocyte subset, are
possessed by all humans (7, 8). In addition, the CD1d
molecule, which is highly conserved (4-6) and expressed by
some breast cancer cells (29, 43), is able to present a
glycolipid, such as 7DW8-5 and its parental glycolipid, 
α-GalCer, both of which activate NKT cells. 7DW8-5, which
possesses a much stronger stimulatory activity against NKT
cells than α-GalCer, has already been shown to display a
more potent antitumor effect than α-GalCer in mice (17).
Therefore, it is conceivable that 7DW8-5 elicits a potent NKT
cell-directed attack on CD1d-expressing breast cancer cells
in humans. In the current study, we demonstrated that human
iNKT cells are able to kill CD1d-expressing human breast
cancer cells in vitro in the presence of 7DW8-5, but not
α-GalCer. The distinct difference in the ability of the two
glycolipids to mediate in vitro killing by human iNKT cells
may be due to the difference in their binding affinity to CD1d
(20) but further investigation is needed to clarify the issue.
For in vivo tumoricidal effects, we opted to test only
7DW8-5, as α-GalCer failed to stimulate antitumor effects
of human iNKT cells in vitro. Since NSG mice lack almost
all mouse-derived adaptive immunity, as well as NK cells
(42), it was possible for human iNKT cells to be adoptively
transferred to NSG mice without facing an immediate GVH
reaction, allowing us to observe the activity of human iNKT
cells in vivo for several weeks. Although not statistically
significantly, the adoptive transfer of human iNKT cells
appeared to suppress tumor growth compared to PBS-treated
NSG mice. It is possible that human iNKT cells may
recognize endogenous glycolipids in the context of CD1d
molecules expressed by the tumor. Nevertheless, the
inclusion of 7DW8-5 concomitant with the adoptive transfer
of human iNKT cells into tumor-challenged NSG mice
significantly inhibited the growth of CD1d+ MDA-MB-231
human breast cancer cells. In addition, it is noteworthy that
the co-administration of human iNKT cells and 7DW8-5 to
a group of tumor-bearing NSG mice resulted in a significant
(p<0.05) increase in the survival rate of mice compared with
that of PBS-treated NSG mice. 7DW8-5 failed to display its
antitumor effect against human breast cancer cells that did
not express human CD1d. In this regard, it is certainly
imperative to investigate whether 7DW8-5 is able to trigger
antitumor effects of human iNKT cells in vivo in the
presence of other cell populations, such as DCs and
macrophages that highly express human CD1d molecules. It
is also plausible that 7DW8-5 would act as an adjuvant to
enhance tumor antigen-specific CD8+ T-cells (25, 43), which
in turn can attack human breast cancer cells regardless of
CD1d expression. The availability of a humanized mouse
model, which possesses an almost entire human immune
system that includes not only human iNKT cells but also
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Figure 2. Experimental scheme and IVIS results showing the in-vivo
tumoricidal effects of human invariant natural killer T- (iNKT) cells in the
presence of glycolipid 7DW8-5. A: Schematic representation of the
experimental procedure for testing in-vivo tumoricidal activity upon the
adoptive transfer of human iNKT cells together with and without 7DW8-5.
B: Non-invasive bioluminescence imaging depicting luciferase expression
in the mammary fat pad, 30 days after injection with MDA-MD-231 cells
co-expressing luciferase and human CD1d. A group of five mice were
treated with phosphate-buffered saline (PBS), whereas groups of four mice
each were adoptively transferred with human iNKT cells or human iNKT
cells with 7DW8-5. C: The graphs show the bioluminescent signal intensity
in the region of interest (ROI), calculated as photons/s/cm2/sr, of all groups
on days 3, 10, 20 and 30 post-MDA-MB-231/Luc/hCD1d challenge. D:
Survival rate of groups of MDA-MB-231/Luc/hCD1d-challenged female
NSG mice that received human iNKT cells with and without 7DW8-5, or
PBS as a control. Statistical analysis of survival rates was performed using
the Gehan–Breslow Wilcoxon test. The data shown are from one of three
independent experiments with similar results. 
CD8+ T-cells and DCs (26, 34, 44), will enable us to address
this aforementioned issue.
In conclusion, we believe that our current study has
provided a proof of principle for using 7DW8-5 as a novel
and potent anticancer immunotherapeutic agent in vivo,
particularly against human CD1d+ tumors. This initial
finding dictates the necessity of a more in-depth mechanistic
study, to investigate the mode of action and efficacy of
7DW8-5 against a myriad of human cancer cells. 
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